EyePoint Email Format

Biotechnology ResearchMassachusetts, United States201-500 Employees

EyePoint is a clinical-stage biotechnology company focused on developing therapeutics for serious retinal diseases. It is headquartered in Watertown, Massachusetts, and operates a commercial manufacturing facility in Northbridge, Massachusetts, with a workforce of 201-500 employees. The lead candidate is a sustained-delivery therapy for VEGF-mediated retinal diseases that uses a selective tyrosine kinase inhibitor within a next-generation bioerodible delivery system. EyePoint is in Phase 3 global pivotal trials for wet age-related macular degeneration, with topline data anticipated in 2026, and has completed a Phase 2 trial in diabetic macular edema with Phase 3 planning underway. The company notes a history of four approved drugs over three decades and tens of thousands of eyes treated, and it trades on Nasdaq under the ticker EYPT.

Sign up for free to view info

Company overview Employee directory